These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 32387055

  • 21. Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR, Abdelfattah NS, Lei J, Shi Y, Marion KM, Morgenthien E, Gune S, Balasubramanian S.
    Ophthalmology; 2020 Oct; 127(10):1360-1370. PubMed ID: 32402555
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM.
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
    Jackson TL, Soare C, Petrarca C, Simpson A, Neffendorf JE, Petrarca R, Muldrew A, Peto T, Chakravarthy U, Membrey L, Haynes R, Costen M, Steel D, Desai R, MERLOT Study Group.
    JAMA Ophthalmol; 2020 Aug 01; 138(8):835-842. PubMed ID: 32644148
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration.
    Schmidt-Erfurth U, Bogunovic H, Sadeghipour A, Schlegl T, Langs G, Gerendas BS, Osborne A, Waldstein SM.
    Ophthalmol Retina; 2018 Jan 01; 2(1):24-30. PubMed ID: 31047298
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Bimonthly, treat-and-extend and as-needed ranibizumab in naïve neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study.
    López Gálvez MI, Arias Barquet L, S Figueroa M, García-Layana A, Ruiz Moreno JM, In-Eye Study Group.
    Acta Ophthalmol; 2020 Nov 01; 98(7):e820-e829. PubMed ID: 32190990
    [Abstract] [Full Text] [Related]

  • 29. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision.
    Shona O, Gupta B, Vemala R, Sivaprasad S.
    Clin Exp Ophthalmol; 2011 Jan 01; 39(1):5-8. PubMed ID: 21040311
    [Abstract] [Full Text] [Related]

  • 30. Randomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes.
    Schefler AC, Fuller D, Anand R, Fuller T, Moore C, Munoz J, Kim RS, RRR Study Group.
    Am J Ophthalmol; 2020 Aug 01; 216():165-173. PubMed ID: 32278771
    [Abstract] [Full Text] [Related]

  • 31. Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration.
    Regillo CD, Busbee BG, Ho AC, Ding B, Haskova Z.
    Am J Ophthalmol; 2015 Nov 01; 160(5):1014-1023.e2. PubMed ID: 26231305
    [Abstract] [Full Text] [Related]

  • 32. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
    Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Weikert R, Fauser S.
    JAMA Ophthalmol; 2020 Sep 01; 138(9):955-963. PubMed ID: 32729888
    [Abstract] [Full Text] [Related]

  • 33. The Value of Prior Response to Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration: A HARBOR Subanalysis.
    Khurana RN, Chang LK, Hill LF, Ghanekar A, Stoilov I.
    Ophthalmol Retina; 2020 Jan 01; 4(1):13-18. PubMed ID: 31416763
    [Abstract] [Full Text] [Related]

  • 34. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C.
    Ophthalmology; 2015 Apr 01; 122(4):822-32. PubMed ID: 25578255
    [Abstract] [Full Text] [Related]

  • 35. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.
    Ricci F, Parravano M, Regine F, Sciamanna M, Tedeschi M, Missiroli F, Varano M.
    Eye (Lond); 2016 Aug 01; 30(8):1077-83. PubMed ID: 27229701
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial.
    Feltgen N, Bertelmann T, Bretag M, Pfeiffer S, Hilgers R, Callizo J, Goldammer L, Bemme S, Hoerauf H.
    Graefes Arch Clin Exp Ophthalmol; 2017 May 01; 255(5):923-934. PubMed ID: 28102456
    [Abstract] [Full Text] [Related]

  • 37. Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA.
    Tufail A, Margaron P, Guerin T, Larsen M.
    Br J Ophthalmol; 2020 May 01; 104(5):672-677. PubMed ID: 31562118
    [Abstract] [Full Text] [Related]

  • 38. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B).
    Hattenbach LO, Feltgen N, Bertelmann T, Schmitz-Valckenberg S, Berk H, Eter N, Lang GE, Rehak M, Taylor SR, Wolf A, Weiss C, Paulus EM, Pielen A, Hoerauf H, COMRADE-B Study Group.
    Acta Ophthalmol; 2018 Feb 01; 96(1):e10-e18. PubMed ID: 28251811
    [Abstract] [Full Text] [Related]

  • 39. Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vision with as-needed ranibizumab.
    Bhisitkul RB, Campochiaro PA, Blotner S, Quezada-Ruiz C, Liu M, Haskova Z.
    Br J Ophthalmol; 2024 Aug 22; 108(9):1216-1225. PubMed ID: 38290802
    [Abstract] [Full Text] [Related]

  • 40. Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study.
    Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J, Tadayoni R, Priglinger S, Wenzel A, Barnes E, Pilz S, Stubbings W, Pearce I, CRYSTAL Study Group.
    Ophthalmology; 2016 May 22; 123(5):1101-11. PubMed ID: 26896124
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.